Skip to main content
Clinical Trials/RPCEC00000075
RPCEC00000075
Not yet recruiting
Phase 2

Clinical evaluation of the effect anti-inflammatory of the extract of Mangifera indica L. (Vimang®) in patient with diagnosis of Bronchial Asthma.

Center of Pharmaceutical Chemistry0 sites88 target enrollmentMarch 13, 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Bronchial Asthma
Sponsor
Center of Pharmaceutical Chemistry
Enrollment
88
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2009
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center of Pharmaceutical Chemistry

Eligibility Criteria

Inclusion Criteria

  • Patients of both sexes, between 20 and 45 years of age, non smokers, who are attended in ambulatory clinics, with diagnosis of persistent moderate asthma that they will be classified by the obstruction degree by spirometry according to Gina 2006\. \-Patient that are of agreement with participating in the clinical trial \-Patients have carried out a Respiratory Functional Test (RFT) with test pre and post bronchial dilator before beginning to take the Vimang® and that it expresses a limitation to the air, reversible or partially reversible flow with bronchial dilator(inhaled Salbutamol).

Exclusion Criteria

  • \- Smoking Patients. \- Pregnancy or nursing. \- Patients that have normal RFT. \- Patient without antecedents of bronchial asthma. \- The patient's negative to fulfill the established dose of the Vimang®. \- The patient's negative to carry out the protocolized investigations. \- Patient that not fulfill with the measures of systematic control: weekly phone calls that include the control of the asthma, besides the biweekly consultation.

Outcomes

Primary Outcomes

Not specified

Similar Trials